Neurofibromatosis Market Dynamics Indicate Upward Trajectory Through 2032, Reports DelveInsight

DelveInsight's "Neurofibromatosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Neurofibromatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Market Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Neurofibromatosis Market Report:
• The Neurofibromatosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
• In February 2025, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on rare diseases and cancer, announced the online publication of pivotal Phase 2b ReNeu trial data in the Journal of Clinical Oncology (JCO). The study assessed mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). These results, from the multi-center, single-arm ReNeu trial, were previously presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
• In November 2024, Alexion, AstraZeneca Rare Disease, and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, reported positive topline results from the Phase 3 KOMET trial-the largest global, randomized, double-blind, placebo-controlled multicenter study in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The results showed that KOSELUGO, an oral and selective MEK inhibitor, demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR), the study's primary endpoint, compared to placebo.
• According to secondary research, Neurofibromatosis Type 1 accounts for approximately 96% of all neurofibromatosis cases, with a prevalence of about 1 in 3,000 births. It affects all genders and races equally, with 50% of cases resulting from spontaneous mutations and the other half from inherited mutations. Neurofibromatosis Type 2 represents around 3% of cases, with a prevalence ranging from 1 in 33,000 to 1 in 87,410 births.
• According to DelveInsight's estimates, in 2023, there were around 16,976 diagnosed prevalent cases of NF-2 across the 7MM, with approximately 10,592 cases reported in the US alone.
• In Italy, NF1 is the most common form of neurofibromatosis, with a prevalence of roughly 1 in 3,164 individuals. Data on NF2, however, remains limited, emphasizing the need for further research. In the UK, NF1 affects about 1 in 4,650 people, according to various studies. A systematic review reported a pooled prevalence of 1 in 3,164 across different populations, indicating that NF1 is a notable health concern both in the UK and worldwide.
• A German study estimated the prevalence of NF1 in 6-year-old children at approximately 1 in 2,996, with a 95% confidence interval ranging from 1 in 2,260 to 1 in 3,984.
• NF2 is relatively rare, with an estimated prevalence of around 1 in 25,000 people in the UK. This estimate comes from regional studies, including research in the North West of England that examined the incidence of vestibular schwannomas linked to NF2.
• A 2023 study in Japan classified NF1 as a rare disease, yet noted it is among the most common genetic disorders globally. Its prevalence is estimated at 1 in 3,000 people in Japan and ranges from 1 in 3,000 to 1 in 6,000 worldwide. NF1 patients reportedly have a 10-15-year shorter life expectancy compared to the general population.
• Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, Merck Sharp & Dohme LLC, SpringWorks Therapeutics, NFlection Therapeutics, Inc., AstraZeneca, Array BioPharma, Recursion Pharmaceuticals, and others
• Key Neurofibromatosis Therapies: FCN-159, NFX-179 Gel, HL-085, RAD001:Everolimus:, Selumetinib granule formulation, Mirdametinib (PD-0325901), NFX-179, Selumetinib, Trametinib, Binimetinib, REC-2282, AZD2014, and others
• The Neurofibromatosis epidemiology based on type-specific cases analyzed that Prevalent Cases of Neurofibromatosis is highest for NF1
• The Neurofibromatosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurofibromatosis pipeline products will significantly revolutionize the Neurofibromatosis market dynamics.

Neurofibromatosis Overview
Neurofibromatosis is a genetic disorder characterized by the growth of noncancerous tumors on nerves throughout the body. It is caused by mutations in specific genes that affect nerve cell growth and development.

Get a Free sample for the Neurofibromatosis Market Report
https://www.delveinsight.com/report-store/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurofibromatosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neurofibromatosis Epidemiology Segmentation:
The Neurofibromatosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Neurofibromatosis
• Prevalent Cases of Neurofibromatosis by severity
• Gender-specific Prevalence of Neurofibromatosis
• Diagnosed Cases of Episodic and Chronic Neurofibromatosis

Download the report to understand which factors are driving Neurofibromatosis epidemiology trends @ Neurofibromatosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurofibromatosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurofibromatosis market or expected to get launched during the study period. The analysis covers Neurofibromatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neurofibromatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neurofibromatosis Therapies and Key Companies
• FCN-159: Fosun Pharmaceutical
• NFX-179 Gel: NFlection Therapeutics, Inc.
• HL-085: Shanghai Kechow Pharma
• RAD001:Everolimus: Novartis
• Selumetinib granule formulation: Merck Sharp & Dohme LLC
• Mirdametinib (PD-0325901): SpringWorks Therapeutics
• NFX-179: NFlection Therapeutics, Inc.
• Selumetinib: AstraZeneca
• Trametinib: Novartis
• Binimetinib: Array BioPharma
• REC-2282: Recursion Pharmaceuticals
• AZD2014: AstraZeneca

Discover more about therapies set to grab major Neurofibromatosis market share @ Neurofibromatosis Treatment Market
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Neurofibromatosis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, Merck Sharp & Dohme LLC, SpringWorks Therapeutics, NFlection Therapeutics, Inc., AstraZeneca, Array BioPharma, Recursion Pharmaceuticals, and others
• Key Neurofibromatosis Therapies: FCN-159, NFX-179 Gel, HL-085, RAD001:Everolimus:, Selumetinib granule formulation, Mirdametinib (PD-0325901), NFX-179, Selumetinib, Trametinib, Binimetinib, REC-2282, AZD2014, and others
• Neurofibromatosis Therapeutic Assessment: Neurofibromatosis current marketed and Neurofibromatosis emerging therapies
• Neurofibromatosis Market Dynamics: Neurofibromatosis market drivers and Neurofibromatosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neurofibromatosis Unmet Needs, KOL's views, Analyst's views, Neurofibromatosis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.